在瘤免疫微环境中重新审视TAM:从NF-κB信号通路的洞察力
1School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 611137, PR China.
概括
瘤相关巨细胞 (TAMs) 调节瘤微环境,并影响癌症免疫疗法. 针对NF-κB通路提供了一个有希望的策略,通过调节TAMs来增强抗瘤免疫力.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 瘤相关巨细胞 (TAMs) 在瘤免疫微环境中至关重要,在瘤进展和抗瘤反应中表现出双重作用.
- 调节TAMs是癌症免疫疗法的重要策略.
- 核因子kappa B (NF-κB) 途径是TAM功能的中央调节者.
研究的目的:
- 审查癌症免疫疗法的当前进展,重点是改善瘤免疫微环境.
- 探索TAMs可以调节治疗效益的机制.
- 讨论NF-κB途径在TAM调节中的作用及其对组合疗法的影响.
主要方法:
- 关于TAMs和癌症免疫治疗的最新研究的文献综述.
- 对调节TAM两极化 (M1/M2) 和透的机制的分析.
- 在临床前和临床研究中检查NF-κB通路向策略.
主要成果:
- TAMs表现出可塑性,影响瘤生长和免疫逃避.
- 准NF-κB通路可以将TAM重编程为抗瘤表型.
- 策略包括促进M1极化,抑制M2极化和控制TAM透.
结论:
- 调节TAMs,特别是通过NF-κB通路,对增强癌症免疫疗法有很大的希望.
- 针对TAM的综合治疗方法需要进一步调查,以解决当前的争议并优化疗效.
相关概念视频
The Tumor Microenvironment
6.7K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
NF-κB-dependent Signaling Pathway
7.5K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Tumor Immunotherapy
573
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
573
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
TGF - β Signaling Pathway
7.5K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.5K


